一项评估 Polatuzumab 在患有弥漫性大 B 细胞淋巴瘤的中国成年参与者的真实临床实践中的有效性和安全性的研究
Polatuzumab 在中国成年弥漫性大 B 细胞淋巴瘤患者的真实临床实践中的有效性和安全性:一项前瞻性、观察性、多中心注册研究
The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习地点
-
-
-
Beijing、中国、100191
- Peking University Third Hospital
-
Beijing、中国、100032
- Peking Union Medical College Hospital
-
Beijing、中国、100730
- Beijing Hospital of Ministry of Health
-
Beijing、中国、100730
- Beijing Tongren Hospital, Capital Medical University
-
Changchun、中国
- The First Bethune Hospital of Jilin University
-
Changsha、中国
- Third Xiangya Hospital of Central South University
-
Changsha、中国、410008
- Xiangya Hospital of Centre-South University
-
Chengdu、中国、610072
- Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
-
Guangzhou、中国、510280
- Zhujiang Hospital, Southern Medical University
-
Guiyang、中国、550004
- Guizhou Cancer Hospital
-
Haikou、中国
- Hainan Cancer Hospital
-
Hohhot、中国、010000
- Affiliated Hospital of Inner Mongolia Medical University
-
Nanchang、中国、330029
- Jiangxi Cancer Hospital
-
Nanjing、中国、211100
- Jiangsu Cancer Hospital
-
Nanjing、中国、210029
- Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
-
Qingdao、中国、DUMMY_VALUE
- The Affiliated Hospital Of Qingdao University
-
Shanghai、中国、200025
- Ruijin Hospital Shanghai Jiaotong University School of Medicine
-
Shanghai、中国、200065
- Tongji Hospital of Tongji University
-
Shenyang、中国、110001
- China Medical University (CMU) First Affiliated Hospital
-
Shijiazhuang、中国
- The Fourth Hospital of Hebei Medical University
-
Taiyuan、中国、030013
- Shanxi Province Cancer Hospital
-
Tianjin、中国、300060
- Tianjin Cancer Hospital
-
Tianjin、中国、300052
- Tianjin Medical University General Hospital
-
Wuhan、中国、430022
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
Wuxi、中国、214023
- Wuxi People's Hospital
-
Xi'an、中国、710061
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University
-
Xuzhou、中国
- The Affiliated Hospital of Xuzhou Medical University
-
Zhengzhou、中国
- Henan Cancer Hospital
-
Ürümqi、中国、830011
- Xinjiang Medical University Cancer Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Participants who will be treated with polatuzumab (known as being recommended and having the intention to be treated with polatuzumab at the time of signing informed consent) or have initiated polatuzumab treatment within three months prior to enrollment and after the indication approval will be observed in this study.
描述
Inclusion Criteria:
- Be diagnosed as DLBCL
- Cohort 1: diagnosed as unfit/frail DLBCL. The unfit/frail is defined as aged 80 years or older, or younger than 80 years but with comorbidity and not tolerant to the standardized dose of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy according to investigator's judgment
- Cohort 2: diagnosis as DLBCL but could not be classified into unfit/frail
- Cohort 3: relapse or refractory to previous treatment
Exclusion Criteria:
- Participant who currently participates in or with plan to participate in any interventional clinical trial
- Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Cohort 1
Unfit/frail participants with DLBCL who are untreated before the administration of polatuzumab and who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years). |
Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.
其他名称:
|
|
Cohort 2
Participants with DLBCL who can not be classified into unfit/frail but are untreated before the administration of polatuzumab and who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years). |
Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.
其他名称:
|
|
Cohort 3
Participants with relapsed or refractory (R/R) DLBCL who have started receiving polatuzumab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 3 years). |
Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
第 1 组和第 2 组:由研究者根据恶性淋巴瘤卢加诺反应标准评估 24 个月无进展生存期 (PFS24)
大体时间:24个月时
|
24个月时
|
|
第 3 组:研究者根据恶性淋巴瘤卢加诺反应标准评估 PFS
大体时间:基线至研究结束 (EOS)(约 38 个月)
|
基线至研究结束 (EOS)(约 38 个月)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
第 3 组:由研究者根据恶性淋巴瘤卢加诺反应标准评估 PFS24
大体时间:24个月时
|
24个月时
|
|
|
第 1、2 和 3 组:下次治疗时间 (TTNT)
大体时间:从开始 polatuzumab 治疗到开始下一线治疗(长达约 38 个月)
|
从开始 polatuzumab 治疗到开始下一线治疗(长达约 38 个月)
|
|
|
第 1、2 和 3 组:由研究者根据恶性淋巴瘤卢加诺反应标准评估的完全缓解率 (CRR)
大体时间:基线长达 EOS(约 38 个月)
|
基线长达 EOS(约 38 个月)
|
|
|
第 1、2 和 3 组:由研究者根据恶性淋巴瘤卢加诺反应标准评估的总体反应率 (ORR)
大体时间:基线长达 EOS(约 38 个月)
|
基线长达 EOS(约 38 个月)
|
|
|
第 1 组和第 2 组:由研究者根据恶性淋巴瘤卢加诺反应标准评估的疾病控制率 (DCR)
大体时间:基线长达 EOS(约 38 个月)
|
基线长达 EOS(约 38 个月)
|
|
|
第 1、2 和 3 组:响应持续时间 (DoR)
大体时间:从首次出现记录的 CR 或部分缓解 (PR) 之日起,到疾病进展、复发或因任何原因死亡之日,以先发生者为准(最长约 38 个月)
|
从首次出现记录的 CR 或部分缓解 (PR) 之日起,到疾病进展、复发或因任何原因死亡之日,以先发生者为准(最长约 38 个月)
|
|
|
第 1 组和第 2 组:无病生存 (DFS)
大体时间:从首次发生有记录的 CR 之日起,到复发或因任何原因死亡之日(以先发生者为准)(最长约 38 个月)
|
从首次发生有记录的 CR 之日起,到复发或因任何原因死亡之日(以先发生者为准)(最长约 38 个月)
|
|
|
第 1 组和第 2 组:由研究者根据恶性淋巴瘤卢加诺反应标准评估无事件生存期 (EFS)
大体时间:从 polatuzumab 治疗开始到任何治疗失败,包括疾病进展、复发、开始新的抗淋巴瘤治疗 (NALT) 或任何原因死亡(先发生者)(最长约 38 个月)
|
从 polatuzumab 治疗开始到任何治疗失败,包括疾病进展、复发、开始新的抗淋巴瘤治疗 (NALT) 或任何原因死亡(先发生者)(最长约 38 个月)
|
|
|
第 1、2 和 3 组:总体生存期 (OS)
大体时间:从 polatuzumab 治疗开始直至任何原因死亡之日(最长约 38 个月)
|
从 polatuzumab 治疗开始直至任何原因死亡之日(最长约 38 个月)
|
|
|
Cohorts 1, 2 and 3: Number of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
大体时间:Up to EOS (approximately 38 months)
|
AEs will be assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
Up to EOS (approximately 38 months)
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- ML44616
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.